1. Home
  2. MEIP vs KDLY Comparison

MEIP vs KDLY Comparison

Compare MEIP & KDLY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MEIP
  • KDLY
  • Stock Information
  • Founded
  • MEIP 2000
  • KDLY 2019
  • Country
  • MEIP United States
  • KDLY United States
  • Employees
  • MEIP 28
  • KDLY N/A
  • Industry
  • MEIP Biotechnology: Pharmaceutical Preparations
  • KDLY
  • Sector
  • MEIP Health Care
  • KDLY
  • Exchange
  • MEIP Nasdaq
  • KDLY NYSE
  • Market Cap
  • MEIP 17.3M
  • KDLY 19.6M
  • IPO Year
  • MEIP 2003
  • KDLY 2024
  • Fundamental
  • Price
  • MEIP $2.60
  • KDLY $2.47
  • Analyst Decision
  • MEIP Hold
  • KDLY
  • Analyst Count
  • MEIP 2
  • KDLY 0
  • Target Price
  • MEIP $7.00
  • KDLY N/A
  • AVG Volume (30 Days)
  • MEIP 7.5K
  • KDLY 13.0M
  • Earning Date
  • MEIP 02-12-2025
  • KDLY 03-04-2025
  • Dividend Yield
  • MEIP N/A
  • KDLY N/A
  • EPS Growth
  • MEIP N/A
  • KDLY N/A
  • EPS
  • MEIP N/A
  • KDLY N/A
  • Revenue
  • MEIP N/A
  • KDLY $2,875,400.00
  • Revenue This Year
  • MEIP N/A
  • KDLY N/A
  • Revenue Next Year
  • MEIP N/A
  • KDLY N/A
  • P/E Ratio
  • MEIP N/A
  • KDLY N/A
  • Revenue Growth
  • MEIP 33.76
  • KDLY N/A
  • 52 Week Low
  • MEIP $2.30
  • KDLY $0.65
  • 52 Week High
  • MEIP $4.42
  • KDLY $5.25
  • Technical
  • Relative Strength Index (RSI)
  • MEIP 37.79
  • KDLY N/A
  • Support Level
  • MEIP $2.55
  • KDLY N/A
  • Resistance Level
  • MEIP $2.79
  • KDLY N/A
  • Average True Range (ATR)
  • MEIP 0.14
  • KDLY 0.00
  • MACD
  • MEIP -0.02
  • KDLY 0.00
  • Stochastic Oscillator
  • MEIP 14.71
  • KDLY 0.00

About MEIP MEI Pharma Inc.

MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.

About KDLY KINDLY MD INC

Kindly MD Inc is a holistically focused pain management clinic and healthcare data company. It offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Its specialty outpatient clinical services are offered on a subscription and fee-for-service basis to augment traditional healthcare. The Company offers evaluation and management, including, but not limited to chronic pain, functional medicine, cognitive behavioral therapy, recovery support services, overdose education efforts, peer support, limited urgent care, preventative medicine, travel services, and hormone therapy.

Share on Social Networks: